Technicals

Surging Earnings Estimates Signal Upside for NetEase (NTES) Stock

NetEase (NTES) appears an attractive pick given a noticeable improvement in the company’s earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company. Analysts’ growing optimism on the earnings prospects of this internet technology company is driving estimates higher, which should get reflected in its stock price. […]

Technicals

Moving Average Crossover Alert: CSX

CSX Corporation CSX could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for CSX broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. This has already started to take place, as the stock has moved lower by 7.1% in the past four weeks […]

Technicals

Moving Average Crossover Alert: Eldorado Resorts

Eldorado Resorts, Inc. ERI could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ERI broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. […]

Technicals

Tsakos Energy (TNP) May Report Negative Earnings: Know the Trend Ahead of Next Week’s Release

The market expects Tsakos Energy (TNP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2019. This widely-known consensus outlook is important in assessing the company’s earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on September 6, 2019, might help the stock move higher if these key numbers are better than expectations […]

Technicals

Brady (BRC) Earnings Expected to Grow: Should You Buy?

Brady (BRC) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended July 2019. This widely-known consensus outlook gives a good sense of the company’s earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on September 6, 2019, might help the stock move higher if these key numbers are better than expectations. […]

Technicals

Analysts Estimate Genesco (GCO) to Report a Decline in Earnings: What to Look Out for

The market expects Genesco (GCO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended July 2019. This widely-known consensus outlook is important in assessing the company’s earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on September 6. […]

Stock Analysts

RH Expects No Impact of China Tariffs on Upcoming Results

RH RH recently announced that the tariffs imposed on existing and new product categories imported from China are unlikely to materially impact results for the current and next fiscal year. This leading luxury home furnishing retailer currently sources approximately 40% of product costs from China, and the incremental 15% tariff impact increases the risk profile. However, the company remains confident that the tariff-related headwinds will more be offset by vendor price reductions and minor price increases. […]

Stock Analysts

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails

AbbVie, Inc. ABBV announced that it is discontinuing development of its small-cell lung cancer (SCLC) candidate rovalpituzumab tesirine or Rova-T after failure of the third study, MERU. The phase III MERU study was evaluating Rova-T as a first-line maintenance therapy for advanced SCLC, a difficult-to treat lung cancer, compared to placebo […]

Stock Analysts

Esperion’s Bempedoic Acid Succeeds in Phase II Diabetes Study

Esperion Therapeutics ESPR announced that the phase II study evaluating a combination of pipeline candidate, bempedoic acid, and Merck’s MRK Zetia (ezetimibe) met primary endpoints. The study was evaluating the regimen in patients with both hypercholesterolemia and type II diabetes and receiving diabetes medications but no statin therapy. […]

Stock Analysts

Here’s Why You Should Invest in Selective Insurance Stock Now

Selective Insurance Group SIGI is well-poised for growth based on improving premiums, geographic expansion and strong capital position. Shares of Selective Insurance Group have rallied 30.7% year to date compared with the industry 's growth of 2.5% and the Zacks S&P 500 composite’s rise of 15%. The company has seen its estimates for 2019 move up 1.6% in the past 30 days, reflecting investor optimism over the stock […]